{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-0586a2-2025-08-13T08:21:27+01:00",
    "date": "2025-08-13T08:21:27+01:00",
    "ocid": "ocds-h6vhtk-0586a2",
    "initiationType": "tender",
    "parties": [
        {
            "id": "GB-PPON-PDBY-6395-VWBP",
            "name": "NHS Blood and Transplant",
            "identifier": {
                "scheme": "GB-PPON",
                "id": "PDBY-6395-VWBP"
            },
            "address": {
                "streetAddress": "500 North Bristol Park",
                "locality": "Bristol",
                "postalCode": "BS34 7QH",
                "country": "GB",
                "countryName": "United Kingdom",
                "region": "UKK12"
            },
            "contactPoint": {
                "email": "james.marshall2@nhsbt.nhs.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.nhsbt.nhs.uk/",
                "classifications": [
                    {
                        "scheme": "UK_CA_TYPE",
                        "id": "publicAuthorityCentralGovernment",
                        "description": "Public authority - central government"
                    }
                ]
            }
        }
    ],
    "buyer": {
        "id": "GB-PPON-PDBY-6395-VWBP",
        "name": "NHS Blood and Transplant"
    },
    "planning": {
        "milestones": [
            {
                "id": "engagement",
                "type": "engagement",
                "description": "NHSBT conducted initial market engagement for ' Supply of Viral Vector Plasmids', via issue of a PIN under the Procurement Contract Regulations (Notice Identifier: 2024/S 000-029545). NHSBT have since updated the requirement to include synthetically produced DNA and/or enzymatically produced DNA. Therefore NHSBT are looking to engage further with suppliers who may have been missed from the initial market engagement, due to synthetic plasmids not being included. If you are interested in taking part in the market engagement, please contact james.marshall2@nhsbt.nhs.uk by no later than 12:00 hrs (GMT) on 12/09/2025. Market engagement is likely to take place via video calls in September 2025. There is no guarantee that a formal procurement process will be launched as a result of this early market engagement exercise, nor that any contract(s) will be placed. No remuneration or compensation etc will be paid to organisations who take part in this early market engagement exercise. Suppliers should take part in this process only on the basis that they fully understand and accept this position.",
                "dueDate": "2025-09-12T23:59:59+01:00",
                "status": "scheduled"
            }
        ],
        "documents": [
            {
                "id": "048226-2025",
                "documentType": "marketEngagementNotice",
                "noticeType": "UK2",
                "description": "Preliminary market engagement notice on Find a Tender",
                "url": "https://www.find-tender.service.gov.uk/Notice/048226-2025",
                "datePublished": "2025-08-13T08:21:27+01:00",
                "format": "text/html"
            }
        ]
    },
    "tender": {
        "id": "C382225",
        "legalBasis": {
            "id": "2023/54",
            "scheme": "UKPGA",
            "uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents"
        },
        "title": "Supply of Plasmids and Synthetic DNA for Viral Vector Manufacture",
        "description": "As part of a preliminary market engagement exercise, NHS Blood & Transplant (NHSBT) are seeking to engage with suppliers of nucleic acids including plasmid DNA; synthetically produced DNA and/or enzymatically produced DNA. The intended use of the nucleic acids by NHSBT includes: a) the GMP grade production of gene therapy vectors such as lentiviral, adeno-associated viral vectors and novel gene therapy vectors, for clinical trials and commercial production where applicable; b) gene therapy vectors suitable for pre-clinical studies, such as toxicology and biodistribution studies and gene therapy vectors suitable for R&D purposes.",
        "items": [
            {
                "id": "1",
                "additionalClassifications": [
                    {
                        "scheme": "CPV",
                        "id": "33698000",
                        "description": "Clinical products"
                    }
                ],
                "deliveryAddresses": [
                    {
                        "region": "UKK11",
                        "country": "GB",
                        "countryName": "United Kingdom"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "value": {
            "amountGross": 8640000,
            "amount": 7200000,
            "currency": "GBP"
        },
        "mainProcurementCategory": "goods",
        "aboveThreshold": true,
        "techniques": {
            "hasFrameworkAgreement": true
        },
        "lots": [
            {
                "id": "1",
                "contractPeriod": {
                    "startDate": "2026-06-15T00:00:00+01:00",
                    "endDate": "2034-06-14T23:59:59+01:00"
                },
                "status": "planning"
            }
        ],
        "communication": {
            "futureNoticeDate": "2025-12-08T23:59:59Z"
        },
        "status": "planning"
    },
    "language": "en"
}